GlaxoSmithKline (GSK) and Jiangsu Walvax Biotech Company (Walvax) sign an agreement to form a JV to produce the measles, mumps and rubella (MMR) and other vaccines in China in a cost and equity sharing deal valued at GB£41.2 M. The deal involves technology transfer and setting up of a vaccines manufacturing facility.